Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lantern Pharma Inc.
< Previous
1
2
Next >
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
August 01, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
June 12, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
May 09, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
May 06, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
May 02, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
April 24, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
April 22, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
March 18, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
March 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
March 11, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
March 05, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
March 04, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
February 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
November 30, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
November 08, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
November 01, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
October 10, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
September 25, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
September 18, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
August 31, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
August 28, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
August 14, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
August 09, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
August 02, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
July 17, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
June 26, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
June 12, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
May 17, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
May 09, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.